TY - JOUR
TI - In vitro activities of tigecycline against recently isolated
Gram-negative anaerobic bacteria in Greece, including
metronidazole-resistant strains
AU - Katsandri, Anastasia
AU - Avlamis, Athina
AU - Pantazatou, Angeliki and
AU - Petrikkos, Georgios L.
AU - Legakis, Nicholas J.
AU - Papaparaskevas,
AU - Joseph
AU - Hellenic Study Grp Gram Negative
JO - Diagnostic Microbiology and Infectious Disease
PY - 2006
VL - 55
TODO - 3
SP - 231-236
PB - EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
SN - 0732-8893
TODO - 10.1016/j.diagmicrobio.2006.01.022
TODO - tigecycline; anaerobes; in vitro study; susceptibility
TODO - The in vitro activity of tigecycline was compared with those of
benzylpenicillin, piperacillin + tazobactam, cefoxitin, imipenem,
metronidazole, clindamycin, and tetracycline against 249 Gram-negative
anaerobic bacteria (158 Bacteroides fragilis group, 27 non fragilis
Bacteroides spp., 44 Prevotella spp., and 20 miscellaneous), recently
isolated from 8 general hospitals in Athens, Greece. Overall tigecycline
MIC50 and MIC90 were 0.25 and 2 mg/L, respectively, whereas B. fragilis
group MICSO and MIC90 were 0.5 and 4 mg/L, respectively. In total, 93%
of the isolates were susceptible to tigecycline (MIC <= 4 mg/L) and no
high-level resistance (MIC >= 32 mg/L) was detected. In addition,
tigecycline exhibited good activity against metronidazole- and
tetracycline-resistant isolates (MIC90, 0.5 and 8 mg/L, respectively).
In summary, tigecycline exhibits good in vitro activity against
Gram-negative anaerobic bacteria isolated in Greece, as well as
stability to the most common occurring resistance mechanisms, attributes
that make this parenteral agent an attractive alternative for use
against infections involving these microorganisms. (c) 2006 Elsevier
Inc. All rights reserved.
ER -